Immunomodulators for allergic respiratory disorders

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 2, 2008, Pages 288-296

  Casale, Thomas B ^a   Stokes, Jeffrey R ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytokine blockers; Immunomodulators; monoclonal antibodies; transcription factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AERODERM; AEROVANT; ALTRAKINCEPT; AMG 317; AVP 13358; CORTICOSTEROID; CRX 675; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; EFALIZUMAB; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 13 ANTIBODY; KELIXIMAB; LUMILIXIMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY IDEC 131; OMALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PROTEIN KINASE SYK INHIBITOR; R 112; R 343; RECOMBINANT INTERLEUKIN 4; RESLIZUMAB; SUPLATAST TOSYLATE; TOLAMBA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGY; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; B LYMPHOCYTE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HAY FEVER; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERSENSITIVITY; INJECTION SITE REACTION; KIDNEY ALLOGRAFT REJECTION; LUNG FUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE POLYP; PRIORITY JOURNAL; RAGWEED; RESPIRATORY TRACT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA;

ANTIBODIES, MONOCLONAL; ASTHMA; B-CELL ACTIVATING FACTOR; CYTOKINES; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; RESPIRATION DISORDERS; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS;

EID: 38949201705     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.11.040     Document Type: Review

References (74)

1. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 (2006) 471-484
2. Casale T.B., Kessler J., and Romero F.A. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol 97 (2006) 454-456
3. Bhattacharjee R.N., and Akira S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 6 (2006) 287-291
4. Hayashi R., and Raz E. TLR9-based immunotherapy for allergic disease. Am J Med 119 (2006) 897 e1-e6
5. Kline J.N. Eat dirt CpG DNA and immunomodulation of asthma. Proc Am Thorac Soc 4 (2007) 283-288
6. Marshall J.D., Abtahi S., Eiden J.J., Tuck S., Milley R., Haycock F., et al. Immunostimulatory sequence DNA linked to Amb a 1 allergen promotes TH1 cytokine expression while downregulating TH2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 108 (2001) 191-197
7. Simons F.E.R., Shiykishima Y., Van Nest G., Eiden J.J., and HayGlass K.T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113 (2004) 1144-1151
8. Higgins D., Rodriquez R., Milley R., Marshall J., Abbate C., Cruz T.D., et al. Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol 118 (2006) 504-510
9. Creticos P.S., Shroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with ragweed-toll-like receptor agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006) 1445-1455
10. Tulic M.K., Fiset P.O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 113 (2004) 235-241
11. Bernstein D.I., Segall N., Nayak A., Casale T., Korenblatt P., and Martins E. Safety and efficacy of the novel vaccine Tolamba in ragweed allergic adults, a dose finding study. J Allergy Clin Immunol 119 suppl (2007) S78-S79
12. Guavreau G.M., Hessel E.M., Boulet L.P., Coffman R.L., and O'Byrne P.M. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 174 (2006) 15-20
13. Krieg A.M. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4 (2007) 289-294
14. Krieg A.M. Development of TLR9 agonists for cancer therapy. J Clin Invest 117 (2007) 1184-1194
15. Tamaoki J., Kondo M., Sakai N., Aoshiba K., Tagaya E., Nakata J., et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Lancet 356 (2000) 273-278
16. Horiguchi T., Tachikawa S., Handa M., Hanazono K., Kondo R., Ishibashi A., et al. Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness. J Asthma 38 (2001) 331-336
17. Yoshida M., Aizawa H., Inoue H., Matsumoto K., Koto H., Komori M., et al. Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients. J Asthma 39 (2002) 545-552
18. Richards M.L., Lio S.C., Sinha A., Tieu K.K., and Sircar J.C. Novel 2-(substituted phenyl) benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem 47 (2004) 6451-6454
19. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M., et al. Interleukin-4 Receptor in Moderate Atopic Asthma: a phase I/II randomized, placebo-controlled trial. Am J Respir Crit Car Med 160 (1999) 1816-1823
20. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 107 (2001) 963-970
21. Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A.M., Postma D.S., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167 (2003) 1655-1659
22. Büttner C., Lun A., Splettstoesser T., Kunkel G., and Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell function. Eur Respir J 21 (2003) 799-803
23. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
24. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., and Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003) 199-204
25. Leckie M.J., Brinke A.T., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
26. Oldhoff J.M., Darsow U., Werfel T., Katzer K., Wulf A., Laifaoui J., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60 (2005) 693-696
27. Gevaert P., Lang-Loidolt D., Lackner A., Stammberger H., Staudinger H., Van Zele T., et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118 (2006) 1133-1141
28. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
29. Plötz S.G., Simon H.U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
30. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2004) 115-119
31. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118 (2006) 1312-1319
32. Bree A., Schlerman F.J., Wadanoli M., Tchistiakova L., Marquette K., Tan X.Y., et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 119 (2007) 1251-1257
33. Blanchard C., Mishra A., Saito-Akei H., Monk P., Anderson I., and Rothenberg M.E. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 35 (2005) 1096-1103
34. Available at: http://www.cambridgeantibody.com/data/assets/pdf_file/11030/CAT-354_Mar07.pdf. Accessed January 11, 2008
35. Available at: http://www.aerovance.com/press_132007.html. Accessed January 11, 2008.
36. Available at: http://www.aerovance.com/aeroderm.html. Accessed September 27, 2007.
37. Nelson H.S., Busse W.W., Israel E., Baker J.W., Charous B.L., Kim K.T., et al. Daclizumab improves asthma control in patients with refractory asthma. J Allergy Clin Immunol 115 suppl (2005) S134
38. Berry M., Brightling C., Pavord I., and Wardlaw A.J. TNF-alpha in asthma. Curr Opin Pharmacol 7 (2007) 279-282
39. Brightling C., Berry M., and Amrani Y. Targeting TNF-α a novel therapeutic approach for asthma. J Allergy Clin Immunol 121 (2008) 5-10
40. Meltzer E.O., Berkowitz R.B., and Grossbard E.B. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 115 (2005) 791-796
41. Zhang D.H., Yang L., Cohn L., Parkyn L., Homer R., Ray P., et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 11 (1999) 473-482
42. Spears M., McSharry C., and Thomson N.C. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 36 (2006) 1494-1504
43. Hashimoto Y., and Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care 25 (2002) 401
44. Gagliardo R., Chanez P., Mathieu M., Bruno A., Constanzo G., Gougat C., et al. Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 168 (2003) 1190-1198
45. Conte M.S., Lorenz T.J., Bandyk D.F., Clowes A.W., Moneta G.L., and Seely B.L. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovasc Surg 39 (2005) 15-23
46. Easthope S., and Jarvis B. Omalizumab. Drugs 61 (2001) 253-260
47. MacGlashan Jr. D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fcε{lunate}RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158 (1997) 1438-1445
48. Lin H., Boesel K., Griffith D., Prussin C., Foster B., Romero F.A., et al. Omalizumab rapidly decreases nasal allergic response and Fcε{lunate}RI on basophils. J Allergy Clin Immunol 113 (2004) 297-302
49. Prussin C., Griffith D.T., Boesel K.M., Lin H., Foster B., and Casale T.B. Omalizumab treatment downregulates dendritic cell Fcε{lunate}RI expression. J Allergy Clin Immunol 112 (2003) 1147-1154
50. Beck L.A., Marcotte G.V., MacGlashan Jr. D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fcε{lunate}RI expression and function. J Allergy Clin Immunol 114 (2004) 527-530
51. Plewako H., Arvidsson M., Petruson K., Oancea I., Holmberg K., Ädelroth E., et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110 (2002) 68-71
52. Noga O., Hanf G., and Kunkel G. Immunological and clinical changes in allergic asthma following treatment with omalizumab. Int Arch Allergy Immunol 131 (2003) 46-52
53. Djukanović R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170 (2004) 583-593
54. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
55. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108 (2001) e36
56. Solér M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 (2001) 254-261
57. Corren J., Casale T.B., Deniz Y., and Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 111 (2003) 87-90
58. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 3 (2007), National Institutes of Health/National Heart, Lung, and Blood Institute, Bethesda (MD). Publication no. 08-4051. Available at www.nhlbi.nih.gov/guildelines/asthma/asthgdln.htm Accessed September 27, 2007
59. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 286 (2001) 2956-2967
60. Ädelroth E., Rak S., Haahtela T., Aasand G., Rosenhall L., Zetterstrom O., et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106 (2000) 253-259
61. Chervinsky P., Casale T., Townley R., Tripathy I., Hedgecock S., Fowler-Taylor A., et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91 (2003) 160-167
62. Hanf G., Noga O., O'Connor A., and Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 23 (2004) 414-418
63. Vignola A.M., Humbert M., Bousquet J., Boulet L.P., Hedgecock S., Blogg M., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59 (2004) 709-717
64. Kuehr J., Brauburger J., Zielen S., Schauer U., Kamin W., Von Berg A., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109 (2002) 274-280
65. Casale T.B., Busse W.W., Kline J.N., Ballas Z.K., Moss M.H., Townley R.G., et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117 (2006) 134-140
66. Leung D.Y.M., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993
67. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., and Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54 (2006) 68-72
68. Vigo P.G., Girgis K.R., Pfuetze B.L., Critchlow M.E., Fisher J., and Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55 (2006) 168-170
69. Krathen R.A., and Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53 (2005) 338-340
70. Spector S.L., and Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 99 (2007) 190-193
71. US Food and Drug Administration statement. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/omalizumabHCP.htm. Accessed September 27, 2007.
72. Prescribing information: summary of product characteristics. Available at: http://www.xolair.com. Accessed September 27, 2007.
73. Limb S.L., Starke P.R., Lee C.E., and Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 120 (2007) 1378-1381
74. Cox L., Platts-Mills T.A.E., Finegold I., Schwartz L.B., Simons F.E.R., and Wallace D.V. AAAAI/ACAAI Joint Task force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120 (2007) 1373-1377